Use of icariin in the preparation of drugs for preventing or treating myelosuppression

An icariin and myelosuppression technology is applied in the field of icariin in the field of preparing drugs for preventing or treating myelosuppression, and can solve the problems of icariin blood cell reduction and the like

Active Publication Date: 2019-10-01
LUNAN PHARMA GROUP CORPORATION
View PDF5 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0011] At present, there is no literature report that icariin has the activity of preventing or treating blood cytopenia, especially myelosuppression caused by radiation or chemicals

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of icariin in the preparation of drugs for preventing or treating myelosuppression
  • Use of icariin in the preparation of drugs for preventing or treating myelosuppression
  • Use of icariin in the preparation of drugs for preventing or treating myelosuppression

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] Embodiment 1: Microemulsion preparation of icarigenin

[0035]

[0036] Preparation process: Weigh the prescription amount of soybean oil, polyoxyethylene-23-lauryl ether, and 1,2-propylene glycol, mix and stir evenly, then add icarigenin to dissolve, and ultrasonic treatment can also be used to speed up the dissolution and obtain clarification The solution is the icarigenin microemulsion preparation. The particle size was measured by a laser particle size analyzer, and the average particle size was 15nm.

Embodiment 2

[0037] Embodiment 2: Microemulsion preparation of icarigenin

[0038]

[0039] Preparation process: Weigh the prescription amount of hydrogenated cocoglyceride, lauroyl polyethylene glycol-32-glyceride, 1,2-propylene glycol, polyethylene glycol 3350, mix and stir evenly, then add icariin to dissolve , can also be ultrasonically treated to accelerate the dissolution to obtain a clear solution, which is the icariin microemulsion preparation. The particle size was measured by a laser particle size analyzer, and the average particle size was 40nm.

Embodiment 3

[0040] Example 3 Icarigenin Injection

[0041]

[0042] Preparation process: Add icariin to the prescribed amount of PEG-400, stir to dissolve, add 0.9% sodium chloride solution to 10L, stir evenly, add 0.5% activated carbon for needles, stir, decarbonize, and obtain.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a medicinal use of anhydroicaritin, especially relates to a use of anhydroicaritin in the preparation of myelosuppression prevention or treatment medicines, and belongs to the field of therapeutic activity of compounds. Anhydroicaritin has unexpected activity in immunity enhancement and hematopoiesis function promotion. Animal in vivo test confirms that the anhydroicaritin substantially improves the leucocyte quantity after chemotherapy, and especially the neutral granulocyte quantity. The anhydroicaritin is an active component capable of resisting the side effects of chemotherapy and improving the chemotherapy effect of tumors, and is of great significance for delaying the life time of cancer patients and improving the survival quality.

Description

technical field [0001] The invention relates to the medical use of icariin, in particular the use of icariin in the preparation of drugs for preventing or treating myelosuppression, and belongs to the field of therapeutic activity of compounds. Background technique [0002] Normal blood contains a large number of cells, including red blood cells that carry oxygen and white blood cells that fight infection. White blood cells include neutrophils, eosinophils, and basophils. Normal blood also contains platelets. Platelets are tiny cellular fragments that trigger blood clotting. Blood cells in the human body are produced by the hematopoietic system. The human hematopoietic system is composed of a small number of bone marrow hematopoietic stem cells and different series of hematopoietic cells at different developmental stages. It is very sensitive to various physical, chemical and metabolic harmful factors in the body, such as body fatigue, exposure to radiation or certain che...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/352A61P7/00A61P7/06
Inventor 赵志全李光艳潘丽红冯芹
Owner LUNAN PHARMA GROUP CORPORATION
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products